These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 26160958)

  • 1. Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients.
    Croyal M; Ouguerram K; Passard M; Ferchaud-Roucher V; Chétiveaux M; Billon-Crossouard S; de Gouville AC; Lambert G; Krempf M; Nobécourt E
    Arterioscler Thromb Vasc Biol; 2015 Sep; 35(9):2042-7. PubMed ID: 26160958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
    Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.
    Hogue JC; Lamarche B; Deshaies Y; Tremblay AJ; Bergeron J; Gagné C; Couture P
    Metabolism; 2008 Feb; 57(2):246-54. PubMed ID: 18191056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
    Croyal M; Tran TT; Blanchard RH; Le Bail JC; Villard EF; Poirier B; Aguesse A; Billon-Crossouard S; Ramin-Mangata S; Blanchard V; Nativel B; Chemello K; Khantalin I; Thedrez A; Janiak P; Krempf M; Boixel C; Lambert G; Guillot E
    Clin Sci (Lond); 2018 May; 132(10):1075-1083. PubMed ID: 29724769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose resveratrol treatment for 2 weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men.
    Dash S; Xiao C; Morgantini C; Szeto L; Lewis GF
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2895-901. PubMed ID: 24072699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial.
    Kim SH; Kim MK; Lee HY; Kang HJ; Kim YJ; Park BJ; Kim HS
    Clin Ther; 2011 Oct; 33(10):1357-64. PubMed ID: 21955937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia.
    Keenan JM
    J Clin Lipidol; 2013; 7(1):14-23. PubMed ID: 23351578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study.
    Ferchaud-Roucher V; Croyal M; Moyon T; Zair Y; Krempf M; Ouguerram K
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):269-279. PubMed ID: 28752209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.
    Tremblay AJ; Lamarche B; Ruel IL; Hogue JC; Deshaies Y; Gagné C; Couture P
    Atherosclerosis; 2006 Sep; 188(1):203-12. PubMed ID: 16337207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low rate of production of apolipoproteins B100 and AI in 2 patients with Anderson disease (chylomicron retention disease).
    Ouguerram K; Zaïr Y; Kasbi-Chadli F; Nazih H; Bligny D; Schmitz J; Aparicio T; Chétiveaux M; Magot T; Aggerbeck LP; Samson-Bouma ME; Krempf M
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1520-5. PubMed ID: 22441101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
    Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
    Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release niacin acutely suppresses postprandial triglyceridemia.
    Usman MH; Qamar A; Gadi R; Lilly S; Goel H; Hampson J; Mucksavage ML; Nathanson GA; Rader DJ; Dunbar RL
    Am J Med; 2012 Oct; 125(10):1026-35. PubMed ID: 22840917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinol-binding protein 4 is an independent factor associated with triglycerides and a determinant of very low-density lipoprotein-apolipoprotein B100 catabolism in type 2 diabetes mellitus.
    Vergès B; Guiu B; Cercueil JP; Duvillard L; Robin I; Buffier P; Bouillet B; Aho S; Brindisi MC; Petit JM
    Arterioscler Thromb Vasc Biol; 2012 Dec; 32(12):3050-7. PubMed ID: 23087360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement.
    Su W; Campos H; Judge H; Walsh BW; Sacks FM
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3267-76. PubMed ID: 9745440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B
    Am J Cardiol; 2004 Sep; 94(5):588-94. PubMed ID: 15342288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.
    Aye MM; Kilpatrick ES; Afolabi P; Wootton SA; Rigby AS; Coady AM; Sandeman DD; Atkin SL
    Diabetes Obes Metab; 2014 Jun; 16(6):545-52. PubMed ID: 24401089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Mediterranean diet with and without weight loss on apolipoprotein B100 metabolism in men with metabolic syndrome.
    Richard C; Couture P; Ooi EM; Tremblay AJ; Desroches S; Charest A; Lichtenstein AH; Lamarche B
    Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):433-8. PubMed ID: 24265415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.